Biweekly Capecitabine Schedule Feasible

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

A biweekly dosing regimen of capecitabine (Xeloda) was well tolerated in a dose-escalation study of metastatic breast cancer patients, allowing safe delivery of higher daily doses than routinely used in practice

ASCO—A biweekly dosing regimen of capecitabine (Xeloda) was well tolerated in a dose-escalation study of metastatic breast cancer patients, allowing safe delivery of higher daily doses than routinely used in practice, Maria Theodoulou, MD, Memorial Sloan-Kettering Cancer Center, reported at the ASCO 2007 meeting (abstract 1045). Capecitabine is typically delivered on a 14-days-on/7-days-off schedule at 1,250 mg/m2 twice daily (total of 2,500 mg/m2/d). In the current study, the agent was given on a 7-days-on/7-days-off schedule with a maximum tolerated dose of 2,000 mg/m2 twice daily (total of 4,000 mg/m2/d).

The design of the single-center, open-label, phase I/II study was based on Norton-Simon mathematical modeling that predicted the optimal dosing schedule for capecitabine. There were no grade 4-5 toxicities, and grade 3 toxicities were transient and manageable. "This new dosing regimen for capecitabine will serve as a platform for combination treatment with targeted therapies," said lead author Clifford Hudis, MD, chief of the Breast Cancer Medicine Service.

Recent Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content